Custom monoclonal antibody reveals HER2+ breast cancer target
Dr Rosemarie Marchan of the Leibniz Research Centre for Working Environment & Human Factors at the TU Dortmund in Germany.

Laboratory products

Custom monoclonal antibody reveals HER2+ breast cancer target

07 Sep, 2023

Published over 2 years ago. See the latest and most current information on Laboratory products.

AMSBIO has supplied a tailor-made monoclonal antibody (mAB) to TU Dortmund researchers in Germany. This mAB aims to decode EDI3's role in breast cancer development, how it's controlled by HER2 signalling, and its therapeutic potential.

HER2+ breast cancer, marked by excessive Human Epidermal Growth Factor Receptor 2 (HER2) expression, is an extremely aggressive cancer subtype. Despite advancements in HER2-targeted therapies, the persistence of treatment resistance, both acquired and inherent, necessitates exploration of alternative therapeutic targets.

Targeting EDI3: A Potential Therapeutic Strategy for HER2-Positive Breast Cancer

Under the leadership of Dr Rosemarie Marchan, a group of researchers has undertaken an extensive study to investigate the clinical significance of EDI3, a glycerophosphodiesterase enzyme linked to choline metabolism, within HER2-positive breast cancer. They utilised the custom monoclonal antibody against EID3, provided by AMSBIO, in their research.

Dr Marchan commented: “We have tested many off-the-shelf antibodies over the years, with little to no success. We have also contracted companies to create a custom antibody for us, but again with limited success. Therefore, we are very thankful a few years ago that we were able to get a great antibody against EID3 from AMSBIO. Using this precious antibody our team has been able to demonstrate that inhibiting EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.”

Read the full case study describing the work of Dr Marchan and her team in the Leibniz Research Centre for Working Environment and Human Factors (IfADo) at the TU Dortmund. 

Monoclonal Antibody Service

With a track record of providing products to numerous industrial and academic projects over the past two decades, AMSBIO has gained widespread recognition as a leading supplier of both ready-made and tailored antibodies. Their services encompass the creation of custom monoclonal antibodies tailored to your specific target antigen, delivering a well-informed and high-quality solution.

More information online

ILM Guide 2026/27

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
Avio 3000 ICP-OES for Wastewater Analyses
Explore more Arrow
Pollution Solutions Online
Next-generation reverse osmosis membranes for more efficient and cost-effective seawater desalination
Explore more Arrow
Petro Online
New test method ASTM D8606 has been officially released
Explore more Arrow
Chromatography Today
Non-invasive flowmeters for real-time monitoring
Explore more Arrow